Want to see BVNRY full AI Analyst Report?
BVNRY Stock Chart & Stats
$8.85
$0.05(0.61%)
At close: 4:00 PM EDT
$8.85
$0.05(0.61%)
Day’s Range― - ―
52-Week Range$8.81 - $12.54
Previous CloseN/A
Volume411.00
Average Volume (3M)793.00
Market Cap
$2.28B
Enterprise Value$1.96K
Total Cash (Recent Filing)$2.29B
Total Debt (Recent Filing)$139.42M
Price to Earnings (P/E)12.7
Beta1.08
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.87
Shares Outstanding237,712,550
10 Day Avg. Volume0
30 Day Avg. Volume793
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.15
Price to Sales (P/S)2.49
P/FCF Ratio6.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Raised Guidance And Contract VisibilityHigher guidance and substantial contracted Public Preparedness revenue improve near-term visibility. The BARDA relationship and more than USD 1.2 billion of orders since 2017 support Bavarian Nordic’s established position in government vaccine procurement.
Travel Health Market MomentumGrowth across rabies, typhoid and tick-borne encephalitis products shows the acquired Travel Health portfolio is gaining traction beyond episodic outbreak orders. Geographic and product diversification can support a more balanced commercial revenue base.
Conservative Balance Sheet And ProfitabilityMinimal leverage and meaningful cash reserves provide financial flexibility for manufacturing, pipeline investment and potential acquisitions. The turnaround to sustained profitability also gives the company greater resilience when public-sector orders or development spending fluctuate.
Bears Say
Lumpy And Mixed Revenue ProfileRevenue remains exposed to episodic government procurement, outbreak-related demand and contract phasing, while the TTM decline indicates limited top-line consistency. This concentration can make capacity planning, earnings forecasting and margin performance less predictable.
U.S. Vimkunya Adoption DelayDelayed U.S. recommendation guidance limits commercial uptake of Vimkunya and creates uncertainty around its DKK 250m 2026 target. A prolonged approval-to-adoption gap could defer product scale-up and reduce the near-term contribution of this growth platform.
Variable Cash Conversion And Pipeline InvestmentAlthough liquidity is strong, cash conversion is uneven and milestone payments can create substantial quarterly outflows. Deliberately staged Lyme and EBV programs also limit near-term pipeline advancement, potentially slowing future growth beyond established products.
Bavarian Nordic News
BVNRY FAQ
What was Bavarian Nordic A/S’s price range in the past 12 months?
Bavarian Nordic A/S lowest stock price was $8.80 and its highest was $12.54 in the past 12 months.
What is Bavarian Nordic A/S’s market cap?
Bavarian Nordic A/S’s market cap is $2.28B.
When is Bavarian Nordic A/S’s upcoming earnings report date?
Bavarian Nordic A/S’s upcoming earnings report date is Aug 21, 2026 which is in 3 days.
How were Bavarian Nordic A/S’s earnings last quarter?
Bavarian Nordic A/S released its earnings results on May 13, 2026. The company reported $0.012 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Bavarian Nordic A/S overvalued?
According to Wall Street analysts Bavarian Nordic A/S’s price is currently Overvalued.
Does Bavarian Nordic A/S pay dividends?
Bavarian Nordic A/S pays a Notavailable dividend of $0.426 which represents an annual dividend yield of N/A. See more information on Bavarian Nordic A/S dividends here
What is Bavarian Nordic A/S’s EPS estimate?
Bavarian Nordic A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bavarian Nordic A/S have?
Bavarian Nordic A/S has 237,712,550 shares outstanding.
What happened to Bavarian Nordic A/S’s price movement after its last earnings report?
Bavarian Nordic A/S reported an EPS of $0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.315%.
Which hedge fund is a major shareholder of Bavarian Nordic A/S?
Currently, no hedge funds are holding shares in BVNRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bavarian Nordic Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.81%
Trailing 12-Months
Company Description
Bavarian Nordic A/S
Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypox (known as IMVAMUNE, IMVANEX, and JYNNEOS), as well as human rabies protection (Rabipur/RabAvert), a tick-borne encephalitis vaccine (Encepur), and an Ebola vaccine (MVABEA). The company also boasts a robust pipeline of investigational therapies. Notably, MVA-BN (freeze-dried) has concluded Phase III trials for smallpox, and MVA-BN RSV is currently in Phase III clinical development for respiratory syncytial virus (RSV). Additionally, ABNCoV2, a candidate for SARS-CoV-2, successfully completed its Phase II clinical trial, and TAEK-VAC is advancing through Phase I/II studies for select advanced HER2 and brachyury-expressing cancers. Bavarian Nordic maintains strategic alliances, including a licensing and collaboration agreement with AdaptVac, alongside further licensing arrangements with the National Cancer Institute and the Public Health Service. Its commercial operations and presence span numerous countries, such as the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, and Japan, reflecting a broad international footprint. Established in 1992, Bavarian Nordic A/S is headquartered in Hellerup, Denmark.
BVNRY Company Deck
BVNRY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear positives: solid Q1 revenue (DKK 1.058b), Travel Health growth (14%), successful global rollout of Vimkunya with DKK 41m in Q1, a meaningful BARDA order that completed a long-term freeze-dried contract and led management to raise full-year revenue guidance to DKK 5.5–5.7b and EBITDA margin to ~28%. Management highlighted strong manufacturing performance, secured Public Preparedness revenues (DKK 2.0b secured with DKK 300–500m expected more), and progress on key R&D readouts (Phase II cell-line interim data due later in 2026). The principal negatives are operational timing risks and one-off cash outflows: U.S. regulatory/publication delays (CDC MMWR) creating headwinds for U.S. uptake of Vimkunya, Encepur inventory/shelf-life timing effects that pressured reported Q1 product sales (though market share and market growth are healthy), negative Q1 operating cash flow impacted by milestone payments, and staged pipeline advancement. Overall, positives (raised guidance, contract wins, product rollouts and strong Travel Health metrics) appear to outweigh the manageable and largely timing-related lowlights.View all BVNRY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors